Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer

In recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Katsunori, Hirakawa, Hitoshi, Suzuki, Mikio, Higa, Teruyuki, Agena, Shinya, Hasegawa, Narumi, Kawakami, Junko, Toyama, Masatomo, Higa, Tomoyo, Kinjyo, Hidetoshi, Kise, Norimoto, Kondo, Shunsuke, Maeda, Hiroyuki, Ikegami, Taro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297315/
https://www.ncbi.nlm.nih.gov/pubmed/37366893
http://dx.doi.org/10.3390/curroncol30060410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297315/
https://www.ncbi.nlm.nih.gov/pubmed/37366893
http://dx.doi.org/10.3390/curroncol30060410

Ejemplares similares